This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
TRENTON, N.J. and WALTHAM, Mass., May 8, 2013 (GLOBE NEWSWIRE) -- The Trenton Health Team (THT) and BG Medicine (Nasdaq:BGMD) today announced that THT has adopted the BGM Galectin-3® test throughout its organization to identify patients at near term risk for heart failure rehospitalization. THT is a community health improvement collaborative that serves the six zip codes of Trenton, New Jersey and is in the process of developing a Medicaid accountable care organization (ACO).
Reducing unplanned readmissions for patients continues to be one of the most urgent and pressing issues facing hospitals in the U.S. today, particularly since October 2012, when the federal Centers for Medicare & Medicaid Services (CMS) enacted new rules that impose significant financial penalties on hospitals with excessive 30-day hospital readmission rates. Among the heart failure population, hospital readmissions can approach up to 25% within 30 days, putting a substantial economic and emotional burden on patients and families, while costing the healthcare system billions of dollars.
"As a collaborative looking to develop an accountable care organization, we are always looking for products and programs that can deliver better quality healthcare while reducing overall costs. THT is committed to reducing unplanned hospital readmissions across the board by 15% in 2013, and the Galectin-3 diagnostic blood test should help us make an impact on readmission rates in one of the most costly patient populations—chronic heart failure patients," stated Dr. Robert Remstein, the President of THT and Vice President for accountable care at Capital Health. "This test can assist our urban based clinicians in identification of patients with heart failure at highest risk for poor outcomes, and guide them towards cost effective care that will improve outcomes and lower overall health care costs."
"Measuring Galectin-3 levels is a simple way to identify patients who are at higher risk of poor outcomes resulting from cardiovascular disease leading to unplanned readmission," stated Eric Bouvier, President and CEO of BG Medicine. "The Trenton Healthcare Team is leading the charge by adopting a broad scope of efforts to reduce costly hospital readmissions."